Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

Stock index futures rose on Friday, with Dow futures leading the charge, as UnitedHealth got a boost after Berkshire Hathaway ...

Telehealth and wellness platform Hims & Hers Health ($HIMS) recently disappointed investors with its mixed second-quarter ...

For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.’s business practices, including whether it has made it too hard for customers to cancel subscriptions, ...

The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

Berkshire Hathaway invests in UnitedHealth; FTC investigates Hims & Hers for advertising practices; U.S. health department ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q2 CY2025, but sales ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock dropped 2.6% on Friday following reports that the Federal Trade Commission has been investigating the telehealth company's business practices for ...

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...